Based on reporting by TechCrunch.
What happened
OpenAI acquired Orchestra Bio, an AI biotech software startup founded four years ago that had raised about $20 million from investors including Andreessen Horowitz, Atria and 8VC.
OpenAI will add Orchestra’s team and technology to its Rosalind AI model for life‑sciences research and the Rosalind Workbench tool, which already serves customers such as Moderna and Novo Nordisk.
AIBeat analysis
This could let Rosalind’s existing customers, including Moderna and Novo Nordisk, use more advanced AI agents that help manage drug discovery tasks such as finance tracking and clinical trial scheduling, potentially streamlining research workflows.